Ftse Mib
34.265,14
-0,32%
DAX
19.962,54
-0,21%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
0,00%
Bitcoin
96.592,47
-0,31%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Enveric Biosciences Inc (ENVB) Enveric Biosciences Inc (ENVB) Notizie

ENVB

Enveric Biosciences (ENVB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ENVB
DataOraFonteTitoloSimboloCompagnia
18/12/202414:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ENVBEnveric Biosciences Inc
12/12/202418:04Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:ENVBEnveric Biosciences Inc
02/12/202414:00Business WireEnveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series CompoundsNASDAQ:ENVBEnveric Biosciences Inc
27/11/202422:36Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ENVBEnveric Biosciences Inc
25/11/202415:00Business WireEnveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like BehaviorNASDAQ:ENVBEnveric Biosciences Inc
22/11/202422:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENVBEnveric Biosciences Inc
14/11/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENVBEnveric Biosciences Inc
14/11/202422:05Business WireEnveric Biosciences Reports Third Quarter 2024 Financial and Corporate ResultsNASDAQ:ENVBEnveric Biosciences Inc
13/11/202417:18Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ENVBEnveric Biosciences Inc
12/11/202415:00Business WireEnveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002NASDAQ:ENVBEnveric Biosciences Inc
04/11/202416:36Business WireEnveric Biosciences Announces Broad Range of Patent IssuancesNASDAQ:ENVBEnveric Biosciences Inc
15/10/202414:00Business WireEnveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003NASDAQ:ENVBEnveric Biosciences Inc
12/10/202401:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENVBEnveric Biosciences Inc
26/09/202414:30Business WireEnveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial WorkshopNASDAQ:ENVBEnveric Biosciences Inc
25/09/202414:30Business WireEnveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug SummitNASDAQ:ENVBEnveric Biosciences Inc
12/09/202415:35Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ENVBEnveric Biosciences Inc
12/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENVBEnveric Biosciences Inc
05/09/202400:43Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ENVBEnveric Biosciences Inc
04/09/202414:00Business WireEnveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ENVBEnveric Biosciences Inc
13/08/202414:00Business WireAries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other ConditionsNASDAQ:ENVBEnveric Biosciences Inc
12/08/202423:30Business WireEnveric Biosciences Reports Second Quarter 2024 Financial and Corporate ResultsNASDAQ:ENVBEnveric Biosciences Inc
25/07/202414:00Business WireEnveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed OrallyNASDAQ:ENVBEnveric Biosciences Inc
15/07/202415:02Business WireAries Science & Technology and Enveric Biosciences Announce Licensing AgreementNASDAQ:ENVBEnveric Biosciences Inc
10/07/202414:00Business WireEnveric Biosciences Announces Patent Granted for Drug CandidateNASDAQ:ENVBEnveric Biosciences Inc
08/07/202423:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENVBEnveric Biosciences Inc
25/06/202414:00Business WireEnveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development CandidateNASDAQ:ENVBEnveric Biosciences Inc
04/06/202400:58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ENVBEnveric Biosciences Inc
30/05/202414:00Business WireEnveric Biosciences to Participate in BIO International Convention 2024NASDAQ:ENVBEnveric Biosciences Inc
15/05/202412:00Business WireEnveric Biosciences Reports First Quarter 2024 Financial and Corporate ResultsNASDAQ:ENVBEnveric Biosciences Inc
14/05/202414:00Business WireEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health DisordersNASDAQ:ENVBEnveric Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ENVB

La tua Cronologia

BIT
SPX
ETF
BIT
NSCIT5144729
Azienda Gardesana Servizi
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network